ALT240705P3500
- 0.05
- 0.000.00%
Altimmune Newsroom
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
Altimmune to Participate at Leerink Partners Therapeutics Forum
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic.
Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic.
Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's chief financial officer. What To Know: Eisenstadt'
Altimmune Drops 15% After Sudden Death of Finance Chief
By Victor Swezey Shares of Altimmune fell Wednesday after Chief Financial Officer Richard Eisenstadt died suddenly. In afternoon trading, the stock was down 15% to $6.31. Shares are still up 83% in
Altimmune Shares Are Trading Lower Following the Passing of CEO Richard Eisenstadt.
Altimmune Shares Are Trading Lower Following the Passing of CEO Richard Eisenstadt.
Express News | Altimmune Shares Down 9% at $6.7 After Co Announces Passing of CFO
Altimmune Initiates Search For New CFO - Quick Facts
Express News | Altimmune Inc: On June 25, Appointed Andrew Shutterly as Acting Chief Financial Officer
Altimmune Announces Passing Of Chief Financial Officer, Richard Eisenstadt; Eisenstadt's Duties Are Being Assumed And Performed Bt Finance And Accounting Team Until Replacement Is Named
Altimmune Announces Passing Of Chief Financial Officer, Richard Eisenstadt; Eisenstadt's Duties Are Being Assumed And Performed Bt Finance And Accounting Team Until Replacement Is Named
Express News | Altimmune Inc: Eisenstadt's Duties Are Being Performed by Finance and Accounting Team
Express News | Altimmune Inc: CFO Richard Eisenstadt Passed Away Unexpectedly on Monday
Press Release: Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company,
Daily Option Tracking | Nvidia rose more than 2% in pre-market trading, multiple call options doubled and increased significantly; Carnival Cruise Line rose nearly 9% after the earnings report, options trading surged.
Tesla's overnight options trading volume was 1.3 million contracts, and the call-to-put ratio decreased to 61%. Multiple call orders were active on the options chain, among which the call with the expiration date on Friday and the exercise price of $190 had the highest trading volume, reaching 122,000 contracts, with an open interest of 35,000 contracts.
B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.
Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.
Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
B.Riley Financial analyst Mayank Mamtani maintains $Altimmune(ALT.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 27.9% and